Literature DB >> 14719800

Substrate specificity of glutaminyl cyclases from plants and animals.

Stephan Schilling1, Susanne Manhart, Torsten Hoffmann, Hans-Henning Ludwig, Claus Wasternack, Hans-Ulrich Demuth.   

Abstract

Glutaminyl cyclases (QC) catalyze the intramolecular cyclization of N-terminal glutamine residues of peptides and proteins. For a comparison of the substrate specificity of human and papaya QC enzymes, a novel continuous assay was established by adapting an existing discontinuous method. Specificity constants (kcat/Km) of dipeptides and dipeptide surrogates were higher for plant QC, whereas the selectivity for oligopeptides was similar for both enzymes. However, only the specificity constants of mammalian QC were dependent on size and composition of the substrates. Specificity constants of both enzymes were equally pH-dependent in the acidic pH-region, revealing a pKa value identical to the pKa of the substrate, suggesting similarities in the substrate conversion mode. Accordingly, both QCs converted the L-beta homoglutaminyl residue in the peptide H-beta homoGln-Phe-Lys-Arg-Leu-Ala-NH2 and the glutaminyl residues of the branched peptide H-Gln-Lys(Gln)-Arg-Leu-Ala-NH2 as well as the partially cyclized peptide H-Gln-cyclo(N epsilon-Lys-Arg-Pro-Ala-Gly-Phe). In contrast, only QC from C. papaya was able to cyclize a methylated glutamine residue, while this compound did not even inhibit human QC-catalysis, suggesting distinct substrate recognition pattern. The conversion of the potential physiological substrates [Gln1]-gastrin, [Gln1]-neurotensin and [Gln1]-fertilization promoting peptide indicates that human QC may play a key role in posttranslational modification of most if not all pGlu-containing hormones.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14719800     DOI: 10.1515/BC.2003.175

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  13 in total

1.  Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding.

Authors:  Kai-Fa Huang; Su-Sen Liaw; Wei-Lin Huang; Cho-Yun Chia; Yan-Chung Lo; Yi-Ling Chen; Andrew H-J Wang
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

2.  Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.

Authors:  Christina Dammers; Kerstin Reiss; Lothar Gremer; Justin Lecher; Tamar Ziehm; Matthias Stoldt; Melanie Schwarten; Dieter Willbold
Journal:  Biophys J       Date:  2017-04-25       Impact factor: 4.033

3.  Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation.

Authors:  Kai-Fa Huang; Yi-Liang Liu; Wei-Ju Cheng; Tzu-Ping Ko; Andrew H-J Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-31       Impact factor: 11.205

4.  Crystallization and preliminary X-ray diffraction studies of the glutaminyl cyclase from Carica papaya latex.

Authors:  Mohamed Azarkan; Bernard Clantin; Coralie Bompard; Hassan Belrhali; Danielle Baeyens-Volant; Yvan Looze; Vincent Villeret; René Wintjens
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2004-10-23

5.  Nectarin IV, a potent endoglucanase inhibitor secreted into the nectar of ornamental tobacco plants. Isolation, cloning, and characterization.

Authors:  S M Saqlan Naqvi; April Harper; Clay Carter; Gang Ren; Adel Guirgis; William S York; Robert W Thornburg
Journal:  Plant Physiol       Date:  2005-10-21       Impact factor: 8.340

6.  2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.

Authors:  Eunsun Park; Kyung-Hee Song; Darong Kim; Minyoung Lee; Nguyen Van Manh; Hee Kim; Ki Bum Hong; Jeewoo Lee; Jie-Young Song; Soosung Kang
Journal:  ACS Med Chem Lett       Date:  2022-08-16       Impact factor: 4.632

7.  Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.

Authors:  Maike Hartlage-Rübsamen; Alexander Waniek; Juliane Meissner; Markus Morawski; Stephan Schilling; Carsten Jäger; Martin Kleinschmidt; Holger Cynis; Astrid Kehlen; Thomas Arendt; Hans-Ulrich Demuth; Steffen Rossner
Journal:  Acta Neuropathol       Date:  2015-02-11       Impact factor: 17.088

8.  Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration.

Authors:  Andreas Becker; Stephanie Kohlmann; Anca Alexandru; Wolfgang Jagla; Fabio Canneva; Christoph Bäuscher; Holger Cynis; Reinhard Sedlmeier; Sigrid Graubner; Stephan Schilling; Hans-Ulrich Demuth; Stephan von Hörsten
Journal:  BMC Neurosci       Date:  2013-10-01       Impact factor: 3.288

9.  Linked production of pyroglutamate-modified proteins via self-cleavage of fusion tags with TEV protease and autonomous N-terminal cyclization with glutaminyl cyclase in vivo.

Authors:  Yan-Ping Shih; Chi-Chi Chou; Yi-Ling Chen; Kai-Fa Huang; Andrew H-J Wang
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

Review 10.  Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges.

Authors:  Holger Cynis; Jeffrey L Frost; Helen Crehan; Cynthia A Lemere
Journal:  Mol Neurodegener       Date:  2016-06-30       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.